A taste of individualized medicine: physicians’ reactions to automated genetic interpretations

Por Lærum, Hallvard, Bremer, Sara, Bergan, Stein, Grünfeld, Thomas
Publicado em 2014

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning

Por Bremer, Sara, Fløisand, Yngvar, Brinch, Lorentz, Gedde-Dahl, Tobias, Bergan, Stein
Publicado no Ther Drug Monit (2015)

Importance of hematocrit for a tacrolimus target concentration strategy

Por Størset, Elisabet, Holford, Nick, Midtvedt, Karsten, Bremer, Sara, Bergan, Stein, Åsberg, Anders
Publicado em 2013

Bodyweight‐adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance

Por Størset, Elisabet, Hole, Kristine, Midtvedt, Karsten, Bergan, Stein, Molden, Espen, Åsberg, Anders
Publicado no Br J Clin Pharmacol (2016)

Response to: ‘Response to: Bodyweight‐adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance’

Por Størset, Elisabet, Hole, Kristine, Midtvedt, Karsten, Bergan, Stein, Molden, Espen, Åsberg, Anders
Publicado no Br J Clin Pharmacol (2017)

The CYP3A biomarker 4β‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation

Por Størset, Elisabet, Hole, Kristine, Midtvedt, Karsten, Bergan, Stein, Molden, Espen, Åsberg, Anders
Publicado no Br J Clin Pharmacol (2017)

Exposure to Mycophenolate and Fatherhood

Por Midtvedt, Karsten, Bergan, Stein, Reisæter, Anna Varberg, Vikse, Bjørn Egil, Åsberg, Anders
Publicado no Transplantation (2017)

Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients – a prospective, randomized study

Por Størset, Elisabet, Åsberg, Anders, Skauby, Morten, Neely, Michael, Bergan, Stein, Bremer, Sara, Midtvedt, Karsten
Publicado no Transplantation (2015)

NFAT‐regulated cytokine gene expression during tacrolimus therapy early after renal transplantation

Por Bremer, Sara, Vethe, Nils T., Skauby, Morten, Kasbo, Margrete, Johansson, Elisabet D., Midtvedt, Karsten, Bergan, Stein
Publicado no Br J Clin Pharmacol (2017)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients

Por Lunde, Ingrid, Bremer, Sara, Midtvedt, Karsten, Mohebi, Beata, Dahl, Miriam, Bergan, Stein, Åsberg, Anders, Christensen, Hege
Publicado em 2014

Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids

Por Kloster-Jensen, Kristine, Sahraoui, Afaf, Vethe, Nils Tore, Korsgren, Olle, Bergan, Stein, Foss, Aksel, Scholz, Hanne
Publicado no J Diabetes Res (2016)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study

Por Stenstrøm Jean, Jørgensen Pål F, Rootwelt Helge, Vethe Nils T, Bremer Sara, Holdaas Hallvard, Midtvedt Karsten, Bergan Stein
Publicado em 2009-07-01

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study

Por Bremer, Sara, Vethe, Nils T, Rootwelt, Helge, Jørgensen, Pål F, Stenstrøm, Jean, Holdaas, Hallvard, Midtvedt, Karsten, Bergan, Stein
Publicado em 2009

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation

Por Åsberg, Anders, Midtvedt, Karsten, van Guilder, Mike, Størset, Elisabet, Bremer, Sara, Bergan, Stein, Jelliffe, Roger, Hartmann, Anders, Neely, Michael N
Publicado em 2013

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling

Por Størset, Elisabet, Holford, Nick, Hennig, Stefanie, Bergmann, Troels K, Bergan, Stein, Bremer, Sara, Åsberg, Anders, Midtvedt, Karsten, Staatz, Christine E
Publicado no Br J Clin Pharmacol (2014)